Fred Beyerlein has joined the board of directors at Velcura Therapeutics Inc., an Ann Arbor biotechnology company developing therapies for osteoporosis. Beyerlein is president and CEO of Rubicon Genomics Inc. in Ann Arbor, and has been an executive at NSC Technologies, Advanced Resin, Sandaro Industries and the Hexcel Corp. He is an expert in market development, license structures, commercial technology identification, strategic plan development, acquisitions and divestitures. Velcura's two other new directors are David A. Jackson, president of Jackson Biotechnology Advisors, and William E. Orabone, founder, president and CEO of Syneptics, a venture financing entity, both of Ann Arbor. Jackson has worked in the biotechnology and pharmaceutical industries for more than two decades, heading his own consulting firm, leading R&D for Genex Corp., and as chief scientist for two other biotechnology firms. Orabone is a veteran of four successful technology startup companies , specializing in capital sourcing, technology acquisition and licensing, strategic partnerships and product introduction.